Long-term real-world effectiveness of allergy immunotherapy in patients with allergic rhinitis and asthma: Results from the REACT study, a retrospective cohort study
| العنوان: | Long-term real-world effectiveness of allergy immunotherapy in patients with allergic rhinitis and asthma: Results from the REACT study, a retrospective cohort study |
|---|---|
| المؤلفون: | Celeste Porsbjerg, Benedikt Fritzsching, Marco Contoli, Mercedes Romano Rodriguez, Lisa Elliott, Sarah Buchs, Julie Rask Larsen, Nick Freemantle |
| المصدر: | The Lancet Regional Health-Europe Fritzsching, B, Contoli, M, Porsbjerg, C, Buchs, S, Larsen, J R, Elliott, L, Rodriguez, M R & Freemantle, N 2022, ' Long-term real-world effectiveness of allergy immunotherapy in patients with allergic rhinitis and asthma : Results from the REACT study, a retrospective cohort study. ', The Lancet Regional Health-Europe, vol. 13, 100275 . https://doi.org/10.1016/j.lanepe.2021.100275Test The Lancet Regional Health. Europe, Vol 13, Iss, Pp 100275-(2022) |
| بيانات النشر: | Elsevier BV, 2022. |
| سنة النشر: | 2022 |
| مصطلحات موضوعية: | Allergy, INCS, intranasal corticosteroids, Effectiveness, short-acting beta2-agonists (SABA), sublingual immunotherapy (SLIT), Allergic rhinitis, HDM, house dust mite, law.invention, AR, allergic rhinitis, intranasal corticosteroids (INCS), Randomized controlled trial, law, house dust mite (HDM), FU, follow-up, inhaled corticosteroids (ICS), SCIT, subcutaneous immunotherapy, retrospective cohort study, Real-world evidence, RCT, randomised clinical trial, biology, Health Policy, subcutaneous immunotherapy (SCIT), Oncology, HRU, health care resource utilisation, Cohort, Public aspects of medicine, RA1-1270, LABA, long-acting beta2-agonists, propensity score matching (PSM), real world evidence (RWE), Research Paper, Allergy immunotherapy (AIT), Retrospective cohort study, PSM, propensity score matching, medicine.medical_specialty, Allergen immunotherapy, allergic rhinitis (AR), Socio-culturale, effectiveness, health care resource utilisation (HRU), AIT, allergy immunotherapy, Rx prescription, Internal medicine, Internal Medicine, medicine, SABA, short-acting beta2-agonists, RWE, real world evidence, Asthma, House dust mite, business.industry, Rx, prescription, asthma, SLIT, sublingual immunotherapy, allergy, medicine.disease, biology.organism_classification, ICS, inhaled corticosteroids, randomised clinical trial (RCT), Allergy immunotherapy, follow-up (FU), Propensity score matching, Allergy immunotherapy (AIT), allergic rhinitis (AR), allergy, asthma, effectiveness, follow-up (FU), house dust mite (HDM), health care resource utilisation (HRU), inhaled corticosteroids (ICS), intranasal corticosteroids (INCS), long-acting beta2-agonists (LABA), propensity score matching (PSM), randomised clinical trial (RCT), real world evidence (RWE), retrospective cohort study, Rx prescription, short-acting beta2-agonists (SABA), subcutaneous immunotherapy (SCIT), sublingual immunotherapy (SLIT), long-acting beta2-agonists (LABA), business |
| الوصف: | Background: Allergen immunotherapy (AIT) is the only causal treatment for respiratory allergy. Long-term real-life effectiveness of AIT remains to be demonstrated beyond the evidence from randomised controlled trials (RCTs). Methods: REACT (Real world effectiveness in allergy immunotherapy) is a retrospective cohort study using claims data between 2007 and 2017. Study eligibility was a confirmed diagnosis of allergic rhinitis (AR), with or without asthma, and AIT. To ensure comparable groups, AIT-treated subjects were propensity score matched 1:1 with control subjects, using characteristic and potential confounding variables. Outcomes were analysed as within (pre vs post AIT) and between (AIT vs control) group differences across 9 years of follow-up (ClinicalTrial.gov: NCT04125888). Findings: 46,024 AIT-treated subjects were matched with control subjects and 14,614 were included in the pre-existing asthma cohort. AIT-treated subjects were 29·5 (16·3) years and 53% were male. Compared to pre-index year, AIT was consistently associated with greater reductions compared to control subjects in AR and asthma prescriptions, including both asthma controller and reliever prescriptions. Additionally, the AIT group had significantly greater likelihood of stepping down asthma treatment (P |
| وصف الملف: | application/pdf |
| تدمد: | 2666-7762 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8ffc8f543ea1923373f6920b4db91b89Test https://doi.org/10.1016/j.lanepe.2021.100275Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....8ffc8f543ea1923373f6920b4db91b89 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 26667762 |
|---|